Abstract
Fundus imaging has emerged as a powerful tool, allowing high-resolution and non-invasive visualization of the fundus microvasculature. Recent advancements in artificial intelligence (AI) have enabled the quantification of fundus microvascular characteristics, paving the way for the development of predictive markers for systemic conditions. In this study, we characterize the fundus microvasculature among 8467 healthy individuals, aged 40-70 years. We employ a fully automated segmentation tool to calculate 12 distinct vessel measures, including tortuosity density, vessel density, average width, fractal dimension, distance tortuosity, and curvature tortuosity for both arteries and veins. We provide reference values for these measures by age and sex, and explore the associations between these fundus vessel measures and various clinical features. Our analysis reveals numerous significant correlations, including connections between fundus arterial measures and cardiovascular measurements, lipid profile, sleep apnea indices, glycemic profile, body composition, and smoking status. This comprehensive analysis of fundus microvasculature anatomy in a large healthy population contributes to the growing field of oculomics and highlights the potential of fundus imaging for earlier detection and monitoring of systemic diseases such as metabolic syndrome, cardiovascular diseases and sleep disorders.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.medrxiv.org/content/medrxiv/early/2021/02/23/2021.02.19.21251487.full.pdf
Funding Statement
Funding E.S. is supported by the Crown Human Genome Center; Larson Charitable Foundation New Scientist Fund; Else Kroener Fresenius Foundation; White Rose International Foundation; Ben B. and Joyce E. Eisenberg Foundation; Nissenbaum Family; Marcos Pinheiro de Andrade and Vanessa Buchheim; Lady Michelle Michels; Aliza Moussaieff; and grants funded by the Minerva foundation with funding from the Federal German Ministry for Education and Research and by the European Research Council and the Israel Science Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Weizmann Institute of Science 10K project data: https://www.medrxiv.org/content/medrxiv/early/2021/02/23/2021.02.19.21251487.full.pdf: Ethical considerations All participants sign an informed consent form upon arrival to the research site. All identifying details of the participants are removed prior to the computational analysis. The 10K cohort study is conducted according to the principles of the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of the Weizmann Institute of Science.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be available by cloud platform to researchers by request.
